Nothing Special   »   [go: up one dir, main page]

SI2874630T1 - Odmerni režim inhibitorjev Janus kinaz (JAK) - Google Patents

Odmerni režim inhibitorjev Janus kinaz (JAK)

Info

Publication number
SI2874630T1
SI2874630T1 SI201331328T SI201331328T SI2874630T1 SI 2874630 T1 SI2874630 T1 SI 2874630T1 SI 201331328 T SI201331328 T SI 201331328T SI 201331328 T SI201331328 T SI 201331328T SI 2874630 T1 SI2874630 T1 SI 2874630T1
Authority
SI
Slovenia
Prior art keywords
jak
inhibitors
dosing regimen
janus kinase
janus
Prior art date
Application number
SI201331328T
Other languages
English (en)
Inventor
Andrea J. Gonzales
Sallie B. Cosgrove
Phyllis B. Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2874630(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of SI2874630T1 publication Critical patent/SI2874630T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SI201331328T 2012-07-20 2013-07-18 Odmerni režim inhibitorjev Janus kinaz (JAK) SI2874630T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
EP13742573.2A EP2874630B1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (1)

Publication Number Publication Date
SI2874630T1 true SI2874630T1 (sl) 2019-04-30

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331328T SI2874630T1 (sl) 2012-07-20 2013-07-18 Odmerni režim inhibitorjev Janus kinaz (JAK)

Country Status (24)

Country Link
US (1) US9522151B2 (sl)
EP (1) EP2874630B1 (sl)
JP (2) JP6022063B2 (sl)
KR (2) KR20150028299A (sl)
CN (2) CN108354938A (sl)
AU (1) AU2013292547B2 (sl)
BR (1) BR112015000808A2 (sl)
CA (1) CA2878867C (sl)
CY (1) CY1121436T1 (sl)
DK (1) DK2874630T3 (sl)
ES (1) ES2707627T3 (sl)
HK (2) HK1209314A1 (sl)
HR (1) HRP20182088T1 (sl)
HU (1) HUE042771T2 (sl)
IN (1) IN2015DN00370A (sl)
LT (1) LT2874630T (sl)
MX (1) MX360857B (sl)
NZ (1) NZ703152A (sl)
PL (1) PL2874630T3 (sl)
PT (1) PT2874630T (sl)
RS (1) RS58242B1 (sl)
SI (1) SI2874630T1 (sl)
WO (1) WO2014015107A1 (sl)
ZA (1) ZA201500134B (sl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2958921T3 (pl) 2013-02-22 2018-01-31 Pfizer Pochodne pirolo[2,3-d]pirymidyny jako inhibitory kinaz janusowych (jak)
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
MX2018004605A (es) 2015-10-16 2018-11-29 Abbvie Inc Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
JP7096592B2 (ja) * 2016-02-16 2022-07-06 ワシントン・ユニバーシティ Ｊａｋ阻害剤およびこれらの利用
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
BR112021014525A8 (pt) * 2019-01-30 2022-11-22 Gargamel Zhuhai Biotech Ltd Inibidor de jak e método de preparação do mesmo
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
CA3201608A1 (en) 2020-12-18 2022-06-23 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3951899A (en) 1998-06-19 2000-01-05 Pfizer Products Inc. Pyrrolo(2,3-d)pyrimidine compounds
MX2011001904A (es) 2008-08-20 2011-03-29 Pfizer Compuestos de pirrolo[2,3-d]pirimidina.

Also Published As

Publication number Publication date
JP2015522620A (ja) 2015-08-06
LT2874630T (lt) 2019-02-11
HUE042771T2 (hu) 2019-07-29
NZ703152A (en) 2016-03-31
PT2874630T (pt) 2019-01-31
IN2015DN00370A (sl) 2015-06-12
US9522151B2 (en) 2016-12-20
US20150126535A1 (en) 2015-05-07
HK1209314A1 (en) 2016-04-01
MX360857B (es) 2018-11-20
AU2013292547A1 (en) 2015-01-22
CN108354938A (zh) 2018-08-03
KR20170034949A (ko) 2017-03-29
RS58242B1 (sr) 2019-03-29
ZA201500134B (en) 2016-08-31
AU2013292547B2 (en) 2017-05-04
PL2874630T3 (pl) 2019-04-30
ES2707627T3 (es) 2019-04-04
CA2878867A1 (en) 2014-01-23
HK1252083A1 (zh) 2019-05-17
DK2874630T3 (en) 2019-01-28
KR20150028299A (ko) 2015-03-13
JP6022063B2 (ja) 2016-11-09
MX2015000871A (es) 2015-05-07
HRP20182088T1 (hr) 2019-02-08
EP2874630A1 (en) 2015-05-27
JP2017019816A (ja) 2017-01-26
BR112015000808A2 (pt) 2017-06-27
EP2874630B1 (en) 2018-12-05
WO2014015107A1 (en) 2014-01-23
CA2878867C (en) 2018-01-09
CY1121436T1 (el) 2020-05-29
CN104470525A (zh) 2015-03-25

Similar Documents

Publication Publication Date Title
HRP20182088T1 (hr) Režim doziranja za inhibitore janus kinaze (jak)
HK1254429A1 (zh) 絲氨酸/蘇氨酸激酶抑制劑
HK1222647A1 (zh) 激酶抑制劑
HK1212683A1 (zh) 多個激酶途徑抑制劑
EP2758051A4 (en) CYANOMETHYLPYRAZOLCARBOXAMIDES AS JANUS KINASEINHIBITORS
EP2710007A4 (en) Kinase Inhibitors
HK1209277A1 (en) 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6-
HK1211574A1 (en) Serine threonine kinase inhibitors
PL2634185T3 (pl) Inhibitory kinazy TYK2
IL229028A0 (en) Kinase inhibitors
HK1213252A1 (zh) 雙環二氫吡啶酮激酶抑制劑
HK1199873A1 (en) Kinase inhibitors
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
HK1213181A1 (zh) 雙環氧雜內酰胺激酶抑制劑